# Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

> **NCT00561418** · PHASE1 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Lymphoma
- Small Intestine Cancer

## Interventions

- **DRUG:** vorinostat
- **OTHER:** Correlative studies

## Key facts

- **NCT ID:** NCT00561418
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2012-11
- **Final completion:** 2013-05
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2015-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00561418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00561418, "Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00561418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*